MSD to Acquire Bispecific Antibody From Curon in Bid to Diversify Portfolio

The novel investigational clinical stage bispecific antibody targets CD3xCD19 to engage T cells with malignant B cells.

Read More


Comments

Leave a Reply

Your email address will not be published. Required fields are marked *